

2023

Patricia D. Pepe Center for Cancer Care ANNUAL REPORT



OSF HEALTHCARE
SAINT ANTHONY MEDICAL CENTER



OSF[®]
HEALTHCARE

FROM THE MEDICAL DIRECTOR'S DESK 2023

Thank you for taking the time to view the 2023 Patricia D. Pepe Center for Cancer Care annual report. It is with great pride that we have been successful in maintaining our American Society of Clinical Oncology's (ASCO), Quality Oncology Practice Initiative (QOPI) and the American College of Radiology's (ACR) Radiation Oncology accreditations. We remain the only cancer center in the region to have triple accreditation. Through independent and impartial review, we believe that accreditation helps us drive and achieve quality in the care we provide our patients.

OSF HealthCare Saint Anthony Medical Center provides a range of services to support cancer patients and their families. The Support Services team at the Center for Cancer Care provides guidance from the time of diagnosis through treatment and beyond. The team comprises nurses, certified research coordinators, social workers, dietitians, medical assistants, radiation therapists, dosimetrists and medical physicists who believe that every patient is unique and deserving of care centered around their individual needs.

In addition to cancer support services, OSF Saint Anthony offers an on-site cancer site nurse navigator who provides key support services and advocates for each patient from diagnosis through treatment and recovery. Social Services and nutritional counseling are also available to better assist with

the needs of patients transitioning to an outpatient setting.

Our cancer committee consists of representatives from all medical specialties in oncology and ancillary services, including dietary, physical therapy and social services, to monitor the overall oncology program. The Center for Cancer Center is committed to providing quality care by utilizing patient care improvement studies that our committee implements.

The Cancer Committee's goals are to monitor cancer screenings, adoption of the National Comprehensive Cancer Network (NCCN) treatment standards, cancer education and cancer prevention programs in line with the Commission on Cancer (COC). We take pride in treating the person, not just the disease.

This year, some new applications were introduced to the oncology service. Cancer IQ is a precision prevention platform that empowers health care providers to engage patients, stratify risk and ensure adherence with the latest evidence for patients who come for mammograms.

Cancer Insights was introduced in our tumor board. It runs a comprehensive patient evaluation using an artificial intelligence (AI) platform to create a concise patient summary, evaluate NCCN Guidelines, consider clinical trials and assist us with maintaining accreditations. It also allows for electronic medical record integration, which creates a note in

the patient's medical record. RadLoop is an automated system designed to decrease lung cancer mortality through early screening using Low-Dose CT for qualified individuals.

In the Spirit of Christ and the example of Francis of Assisi, the Mission of OSF HealthCare is to serve persons with the greatest care and love in a community that celebrates the Gift of Life. The strength and courage of our patients and their loved ones are demonstrated to us continually. They are the reason we strive to provide the highest quality outcomes with the greatest care and love. We thank our Mission Partners, supporters, volunteers and donors who make our achievements possible.




IFTEKHAR U. AHMAD, MD, MS

Radiation Oncologist
Medical Director, Oncology Services
Chair, Cancer Committee



EDWARD ARIBISALA MS, MBA, ACHE

Director, Oncology Services



2023 Cancer Committee

The Cancer Committee is a multidisciplinary group of physicians from various specialties, as well as representatives from departments and community partners that provide support and management of cancer care. This committee guides cancer studies, quality improvement and cancer-related policies and programs for the Center for Cancer Care at OSF Saint Anthony.



CANCER COMMITTEE CHAIR Iftekhar Ahmad, MD, MS

CANCER LIAISON PHYSICIAN Alyssa Ceilesh, DO

CANCER COMMITTEE COORDINATORS

Cancer Registry Coordinator Amy Clendening, CTR

Cancer Program Administrator Edward Aribisala, MBA

Quality Improvement Coordinator Akta Patel, BS, RTT, MBA

Cancer Registry Quality Coordinator Lynn Kiehl, CTR

Community Outreach Coordinator Edward Aribisala, MS, MBA

Clinical Research Coordinator Karen Blatter, RN, BSN, OCN

Psychosocial Services Coordinator Karen Gessner, MSW

Survivorship Program Coordinator Peggy Malone, RN, BS, OCN

CANCER COMMITTEE MEMBERS

American Cancer Society Michelle Hicks-Turner, MPH
Nicole Robertson

Clinical Trials Iftekhar U. Ahmad, MD, MS

Diagnostic Radiology Stephen Lehnert, MD

General Surgery Eileen O'Halloran, MD, MS

Genetics Peggy Rogers, MSN, APRN, AOCNP

Medical Oncology Mete Korkmaz, MD

Nutrition Services Jason Crum, RD

Oncology Nurse Julie Cline, BSN, MS, OCN

Palliative Care Jean Kriz, MD

Pathology Rada Gerbi, MD

Pharmacy Erich Balsman, PharmD, BCPS

Radiation Oncology George Bryan, MD

Rehabilitation Services Barbara Gutierrez, PT

TUMOR REGISTRY

Cancer registrars are data information specialists who collect and report cancer statistics. Cancer registrars capture the complete history, diagnosis, treatment and health status of every cancer patient in the U.S.

The Certified Tumor Registrar (CTR®) credential sets the standard for professional competence in the cancer registry field. It is nationally recognized in the recruitment and retention of registry personnel. National Cancer Registrars Association’s certification board – the Council on Certification – oversees the CTR exam administration and credential maintenance.

Cancer registrars collect the data that provides essential information to researchers, health care providers and public health officials to monitor and advance cancer treatments, conduct research and improve cancer prevention and screening programs.

By collecting the data that makes up the cancer history of each cancer patient, information can be provided to researchers, health care providers and public health officials to help:

- Monitor cancer trends over time
- Evaluate cancer patterns in populations and identify high-risk groups
- Guide planning and evaluation of cancer control programs
- Set priorities for allocating health resources

- Study cancer causes and prevention strategies
- Public reporting of outcomes
- Follow College of American Pathologist protocols and synoptic reporting
- Monitor compliance with guidelines
- Serve as a resource on Commission on Cancer (CoC) standards TUMOR REGISTRARS

Working with the Cancer Committee, providers, and administrators are these hardworking tumor registrars:

Diane Aaby, CTR

Diane has 22 years of CTR experience and has been an OSF Mission Partner since 2017.

Amy Clendening, BSN, OCN, CTR

Amy has been an OSF Mission Partner since 2001 and has been with the Cancer Tumor Registry for the past two years.

Lynn Kiehl, CTR


For the past 23 years, Lynn has worked as a Mission Partner in the Patricia D. Pepe Center for Cancer Care and has been doing cancer registry for 22 years.


Tanya Magnuson, CTR

A Mission Partner since 1995, Tanya has been doing cancer registry for 18 years.

2022 CENTER FOR CANCER CARE: STAGING DISTRIBUTION

STAGE	PERCENTAGE
0	4%
I	27%
II	10%
III	13%
IV	18%
88	20%
Unk	10%







2022 CENTER FOR CANCER CARE: GENDER DISTRIBUTION

In 2022, OSF Saint Anthony had 838 total cases (48.6% male and 51.4% female), with 81.3% of patients still surviving.

■ Female
■ Male




2022 CENTER FOR CANCER CARE: PRIMARY ANALYTIC CANCER SITES




2022 CENTER FOR CANCER CARE-NATIONAL CANCER DATABASE: COUNTY OF RESIDENCE AT DIAGNOSIS DISTRIBUTION



2022 CENTER FOR CANCER CARE-NATIONAL CANCER DATABASE: MAJOR CANCER SITES OSF VS. STATE AND NATIONAL COMPARISON



2022 CENTER FOR CANCER CARE: TOP 10 SITES BY GENDER DISTRIBUTION



CLINICAL TRIALS



KAREN M. BLATTER RN, BSN, OCN, CCRC
Oncology Nurse-Lead Research Coordinator

INTRODUCTION

The Center for Cancer Care research team screens every cancer patient for clinical trial eligibility. Participation in a clinical trial is a valuable way for patients, their families and caregivers to access health care and investigational treatments. The Center for Cancer Care research team partners with the University of Illinois Chicago to offer a variety of clinical trials designed to meet our community's needs.

RESEARCH: THE FOUNDATION OF PROGRESS

Clinical trials may be sponsored by the National Cancer Institute (NCI), pharmaceutical companies, academic institutions and local scientists for different reasons.

For example:

- Treatment trials test how safe and useful a new treatment or way of using existing treatments is for people with cancer. Test treatments may include drugs, approaches to surgery, radiation therapy or combinations of treatments. *
- Screening trials test how effective screening tests are for healthy people. The goal of these trials is to discover screening tools or methods that reduce deaths from cancer by finding it earlier. *

In addition, some clinical trials are designed to:

- Improve quality of life and supportive care.
- Help people with cancer live longer than with current treatment.

- Help delay the return of the cancer.
- Test new ways to find, prevent and treat cancer.
- Test ways to prevent side effects of cancer treatment.
- Test ways to prevent cancer from recurring.

There are also studies that simply involve the donation of tumor tissue collected at the time of a cancer diagnosis or a few extra tubes of blood. These are used to:

- Study tissue and blood samples to find tumor markers.
- Find other signals of cancer, which may be used to detect cancer through routine blood tests, even before any symptoms arise.

Many clinical trials are conducted at academic institutions and medical centers in urban (i.e., large cities) and surrounding suburban communities. Those trials provide valuable information about cancer in general, but people who live in rural communities may have different experiences and needs than those who live in urban areas. Clinical trials conducted at OSF HealthCare in the Rockford area contribute additional insight and information uniquely beneficial to members of our local community and other similar communities.

SAMPLE OF CURRENT CLINICAL TRIALS

LUNG CANCER TRIALS

EARLY-STAGE NSCLC

THE ALCHEMIST* SCREENING TRIAL (A151216):

For patients with early-stage resected non-small cell lung cancer, a small sample of the tumor is tested for the presence of certain gene mutations or changes to determine which “targeted therapy” treatment trial is best.

ADVANCED-STAGE NSCLC

LungMAP Screening Trial:

For patients with advanced-stage non-small cell lung cancer, a tumor sample is tested for genetic changes to see if the patient might benefit from a targeted drug study.

CRIZOTINIB TREATMENT TRIAL (E4512):

This treatment trial is testing to see if crizotinib improves the odds that the cancer will not return in patients who have ALK gene changes.

ALCHEMIST chemo-IO “ACCIO” (A081801):

This treatment trial is testing if pembrolizumab can improve survival and the length of time it takes for the cancer to come back in patients with resected early-stage lung cancer.

S1900G:

This is a study for people whose non-small cell lung cancer progressed after treatment with osimertinib (Tagrisso) and has changes in the EGFR and MET genes.

S1900E:

This study tests a drug called sotorasib, which fights cancer by targeting the KRASG12C gene, which can cause the cancer to grow and spread.

Since Winnebago County has a higher incidence of lung cancer cases than the National average, OSF Saint Anthony has screening and treatment trials that study targeted treatments for patients with lung cancer.

SAMPLE OF CURRENT CLINICAL TRIALS

BREAST CANCER TRIAL

A011801-COMPASSHER2-RD:

For patients with HER2-positive breast cancer who received treatment with chemotherapy and anti-HER2 targeted therapies followed by surgery and the cancer was still present in the breast or lymph nodes. This study is being done to find out whether the combination of T-DM1 and tucatinib is better than treatment with T-DM1 alone at preventing cancer from returning.

A012301 OptimICE-PCR:

For patients with Triple-negative breast cancer who completed chemotherapy and pembrolizumab, followed by breast surgery, and no remaining cancer was found during the surgery. This study is being done to find out whether an observation is as effective as six more months of pembrolizumab after surgery at preventing cancer from coming back.

Last year, we noticed a slight increase in the number of patients with HER2-positive and triple-negative breast cancers, so we opened clinical trials targeting those cancer types.

BLOOD COLLECTION AND PREVENTION STUDIES

BLOOD COLLECTION

A212102 Multicancer Early Detection Blood Tests:

This study is collecting blood samples from patients with newly diagnosed cancer to look for signals of cancer that may be present in the blood and can help detect cancer early through blood tests.

A151804 Establishment of a national biorepository to advance studies of immune-related adverse events:

This study is collecting data and samples from patients treated with immunotherapy to study its side effects and understand better how to predict, prevent, and treat these side effects.

PREVENTION

A211901 Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions:

A research study to test an intervention using text messaging or written booklets to help people quit smoking.

Participation in clinical trials that focus on prevention and early detection of cancer could improve the lives of those who live in the Rockford area and around the world.

More information about these and other clinical trials can be found at clinicaltrials.gov.

** Reference: What Are Cancer Research Studies? - NCI (2023)*

MEET THE TEAM

SENIOR MANAGEMENT



A.J. Querciagrossa
Chief Executive Officer,
Western Region



Paula Carynski, RN, MS
President, OSF HealthCare
Saint Anthony Medical Center



Lisa A. Davis, MD
Vice President,
Chief Medical Officer



Jedediah Cantrell
Vice President,
Operations and Special Projects



Wayne Laramie
Vice President,
Chief Nursing Officer



Kerry Hill
Chief Financial Officer

MEDICAL TEAM



Iftekhar Ahmad, MD
Medical Director, Radiation Oncology



George Bryan, MD
Radiation Oncology



Alyssa Ceilesh, DO
Hematology, Medical Oncology



Kent Hoskins, MD
Cancer Genetics, Hematology,
Medical Oncology



Mete Korkmaz, MD
Hematology, Medical Oncology



Eileen O'Halloran, MD
Surgical Oncology



Jeffrey Boyd, APRN
Hematology, Medical Oncology



Anne Celner, APRN
Hematology, Medical Oncology



Margaret Rogers, APRN
Cancer Genetics, Hematology,
Medical Oncology

MEET THE TEAM

MANAGEMENT TEAM




Edward Aribisala, MS, MBA
Director



Julie Cline, RN, MS, OCN
Medical Oncology Nurse Manager



Akta Patel, RTT, MS
Radiation Oncology Manager



Our cancer report is prepared annually and is dedicated to our patients and their families who continue to inspire us with their courage.

For more information about cancer services and programs, or to refer a patient to the Patricia D. Pepe Center for Cancer Care at OSF HealthCare Saint Anthony Medical Center, call (815) 227-2273 or visit osfsaintanthony.org.

References

- American College of Surgeons. 2020. *Commission on Cancer: Improving outcomes for patients with cancer*. facs.org/quality-programs/cancer/coc
- American College of Surgeons. 2020. *National Cancer Database*. facs.org/quality-programs/cancer/ncdb
- American Society of Clinical Oncology and Association for Clinical Oncology. 2020. *Quality Oncology Practice Initiative*. practice.asco.org/quality-improvement/quality-programs/qopi-certification-program



OSF HealthCare Saint Anthony Medical Center
5666 E. State St., Rockford, Illinois • osfsaintanthony.org